Eric Quemeneur - Transgene President
| TRGNF Stock | USD 1.59 0.00 0.00% |
President
Dr. Eric Quemeneur, Ph.D., was Executive Vice President, Director of Research Development and Member of the Management Committee at Transgene since 2014. Before joining Transgene he served as Director of Programs and Reclamation in the Life Sciences Department of the CEA, after a 20year career in that organization. His responsibilities included managing the Research and Development programs and transferring them into applications, leading multidisciplinary teams and developing national and international alliances. He is a biochemical engineer, INSA Lyon, with a PhD in science, a D.U. degree in Industrial Pharmaceuticals from Universite Claude Bernard Lyon 1 and a Certificate in Research Management from Universite Pierre et Marie Curie Paris VI. He is the author of some 80 publications in international scientific journals. since 2014.
| Age | 58 |
| Tenure | 10 years |
| Phone | 33 3 88 27 91 00 |
| Web | https://www.transgene.fr |
Transgene Management Efficiency
The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | PRESIDENT Age | ||
| Jared Brandman | National Vision Holdings | 47 | |
| Alex Wilkes | National Vision Holdings | N/A | |
| William Treacy | LB Foster | 64 | |
| Gregory Lippard | LB Foster | 55 | |
| Craig Apolinsky | GMS Inc | 57 | |
| Leslie Kratcoski | GMS Inc | N/A | |
| Brian Kelly | LB Foster | 64 | |
| Scott Deakin | GMS Inc | 58 | |
| Patrick Moore | National Vision Holdings | 60 | |
| Chris Feng | Sea | 41 | |
Management Performance
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 |
Transgene SA Leadership Team
Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maud MD, VP Officer | ||
| Eric Quemeneur, Executive Vice President Vice President - Research & Development, Member of the Management Committee | ||
| Gaelle Stadtler, VP HR | ||
| JeanPhilippe Del, Vice President - Finance, Member of the Management Committee | ||
| Elisabetta Castelli, Director of Investor Relations | ||
| Hedi Brahim, CEO Director | ||
| Lucie Larguier, Director IR | ||
| Steven RPh, VP Officer | ||
| LLM JD, Gen VP | ||
| Philippe Slos, Head Laboratory |
Transgene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.39) % | |||
| Current Valuation | 152.15 M | |||
| Shares Outstanding | 100.2 M | |||
| Shares Owned By Institutions | 1.70 % | |||
| Price To Earning | (7.42) X | |||
| Price To Book | 0.02 X | |||
| Price To Sales | 10.71 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Transgene Pink Sheet
Transgene financial ratios help investors to determine whether Transgene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.